钇-90放射栓塞治疗神经内分泌肿瘤:国际多中心回顾性研究
该国际多中心回顾性研究分析了297例神经内分泌肿瘤(NEN)肝转移患者接受90Y放射栓塞(90Y RE)的疗效与生存。结果显示3个月疾病控制率83.5%、12个月50.9%,中位总生存38.9±33.0个月;高肿瘤分级和高肿瘤负荷与总生存显著降低相关。90Y RE可作为生长抑素类似物治疗后进展、肝为主病变患者的二线重要替代选择,尤其可考虑替代肽受体放射性核素治疗。
要点
- 90Y RE后3个月疾病控制率83.5%,12个月为50.9%。
- 总体中位总生存38.9±33.0个月。
- 高肿瘤分级(P<0.006)和高肿瘤负荷(P=0.001)与总生存显著降低相关。
核心结论
- 90Y RE可能成为生长抑素类似物治疗后进展、肝为主病变患者中替代肽受体放射性核素治疗的二线重要选择。
研究设计与样本
- 国际多中心回顾性分析,共纳入297例神经内分泌肿瘤患者90Y RE前的血管造影评估。
- 分析基线特征、影像学及90Y RE相关参数,采用RECIST 1.1评估肿瘤反应并收集生存数据。
- 采用Kaplan-Meier曲线和log rank检验比较不同组间平均总生存,P<0.05为差异有统计学意义。
主要发现
- 90Y RE后3个月按RECIST 1.1评估的疾病控制率为83.5%,12个月为50.9%。
- 整个队列总生存为38.9±33.0个月。
- 高肿瘤分级(P<0.006)和高肿瘤负荷(P=0.001)均与总生存显著降低相关。
- 肝外转移(P=0.335)和转移性血管化模式类型(P=0.460)对总生存无影响。
- 二线治疗患者总生存略长于挽救治疗患者(44.8 vs. 30.6个月,P=0.078),但差异无统计学意义;重度预处理患者肝内和全局无进展生存较二线治疗患者显著降低(P=0.011和P=0.010)。
关键数值与推荐
- 肿瘤反应评估采用RECIST 1.1标准。
- 疾病控制率:3个月83.5%,12个月50.9%。
- 总生存:整个队列38.9±33.0个月;二线治疗44.8个月 vs. 挽救治疗30.6个月(P=0.078)。
- 高肿瘤分级P<0.006、高肿瘤负荷P=0.001与总生存显著降低相关。
- 肝内和全局无进展生存:重度预处理 vs. 二线治疗分别P=0.011和P=0.010。
临床怎么用
- 对于生长抑素类似物治疗后进展、肝为主病变的神经内分泌肿瘤患者,90Y RE可作为二线治疗选择。
- 高肿瘤分级或高肿瘤负荷患者接受90Y RE时总生存可能较差,需综合评估。
- 肝外转移的存在或转移性血管化模式类型不应作为排除90Y RE的依据。
局限性
- 本研究为回顾性分析,可能存在选择偏倚。
- 原文未报告前瞻性随机对照数据,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In neuroendocrine neoplasms (NENs), the presence of distant metastases has a severe impact on survival leading to a relevant decrease in the 5-y survival rate. Here, 90Y radioembolization (90Y RE) might be an important treatment option; however, data to support clinical benefits for 90Y RE are scarce. Therefore, the purpose of this study was to analyze the use of 90Y RE in NEN patients with hepatic metastases in an international, multicenter retrospective analysis and assess the potential role of 90Y RE in a multimodal treatment concept. Methods: In total, 297 angiographic evaluations in NEN patients before 90Y RE were analyzed. Baseline characteristics and parameters derived from imaging evaluation and 90Y RE were analyzed. Tumor response was assessed using RECIST 1.1, and survival data were collected. Mean overall survival (OS) between different groups was compared using Kaplan-Meier curves and the log rank test. A P value of less than 0.05 indicated statistical significance. Results: After 90Y RE, the disease control rate according to RECIST 1.1 was 83.5% after 3 mo and 50.9% after 12 mo. OS in the entire population was 38.9 ± 33.0 mo. High tumor grade (P < 0.006) and high tumor burden (P = 0.001) were both associated with a significant decrease in OS. The presence of extrahepatic metastases (P = 0.335) and the type of metastatic vascularization pattern (P = 0.460) had no influence on OS. Patients who received 90Y RE as second-line therapy had a slightly longer but not statistically significant OS than patients who had 90Y RE in a salvage setting (44.8 vs. 30.6 mo, P = 0.078). Hepatic and global progression-free survival after 90Y RE was significantly decreased in heavily pretreated patients, compared with patients with second-line therapy (P = 0.011 and P = 0.010, respectively). Conclusion:90Y RE could be an important alternative to peptide receptor radionuclide therapy as second-line treatment in patients with progressive liver-dominant disease pretreated with somatostatin analogs.
引用
- Schaarschmidt BM, Wildgruber M, Kloeckner R, et al. 90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study. J Nucl Med. 2021. PMID: 34475236. doi:10.2967/jnumed.121.262561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。